1093 related articles for article (PubMed ID: 1509400)
1. Thrombospondin levels in patients with malignancy.
Tuszynski GP; Smith M; Rothman VL; Capuzzi DM; Joseph RR; Katz J; Besa EC; Treat J; Switalska HI
Thromb Haemost; 1992 Jun; 67(6):607-11. PubMed ID: 1509400
[TBL] [Abstract][Full Text] [Related]
2. Thrombospondin, a potentiator of tumor cell metastasis.
Tuszynski GP; Gasic TB; Rothman VL; Knudsen KA; Gasic GJ
Cancer Res; 1987 Aug; 47(15):4130-3. PubMed ID: 3607754
[TBL] [Abstract][Full Text] [Related]
3. Thrombospondin binds to the surface of human osteosarcoma cells and mediates platelet-osteosarcoma cell interaction.
Clezardin P; Serre CM; Trzeciak MC; Drouin J; Delmas PD
Cancer Res; 1991 May; 51(10):2621-7. PubMed ID: 1708697
[TBL] [Abstract][Full Text] [Related]
4. Thrombospondin and other possible related matrix proteins in malignant and benign breast disease. An immunohistochemical study.
Wong SY; Purdie AT; Han P
Am J Pathol; 1992 Jun; 140(6):1473-82. PubMed ID: 1351369
[TBL] [Abstract][Full Text] [Related]
5. Localization of thrombospondin and its cysteine-serine-valine-threonine-cysteine-glycine-specific receptor in human breast carcinoma.
Tuszynski GP; Nicosia RF
Lab Invest; 1994 Feb; 70(2):228-33. PubMed ID: 7511188
[TBL] [Abstract][Full Text] [Related]
6. Circulating intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1) and E-selectin in urological malignancies.
Perabo F; Sharma S; Gierer R; Wirger A; Fimmers R; Steiner G; Adam M; Schultze-Seemann W
Indian J Cancer; 2001 Mar; 38(1):1-7. PubMed ID: 14758878
[TBL] [Abstract][Full Text] [Related]
7. Plasma thrombospondin as an indicator of intravascular platelet activation in patients with vasculitis.
McCrohan MB; Huang SW; Sleasman JW; Klein PA; Kao KJ
Thromb Haemost; 1987 Oct; 58(3):850-2. PubMed ID: 2963403
[TBL] [Abstract][Full Text] [Related]
8. [Analysis of adhesive proteins on the surface of platelets from the patients with lung cancer: studies in histological type and clinical stage].
Soga T; Nomura S; Kido H; Yamaguchi K; Fukuroi T; Yanabu M; Kokawa T; Yasunaga K
Rinsho Ketsueki; 1992 Sep; 33(9):1121-7. PubMed ID: 1433932
[TBL] [Abstract][Full Text] [Related]
9. The role of thrombospondin-1 in tumor progression and angiogenesis.
Tuszynski GP; Nicosia RF
Bioessays; 1996 Jan; 18(1):71-6. PubMed ID: 8593167
[TBL] [Abstract][Full Text] [Related]
10. Serum big endothelin-1 levels in female patients with breast cancer.
Yildirim Y; Gunel N; Coskun U; Sancak B; Bukan N; Aslan S; Cetin A
Int Immunopharmacol; 2008 Aug; 8(8):1119-23. PubMed ID: 18550016
[TBL] [Abstract][Full Text] [Related]
11. Are angiogenic factors, cytokines, and soluble adhesion molecules prognostic factors in patients with renal cell carcinoma?
Dosquet C; Coudert MC; Lepage E; Cabane J; Richard F
Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2451-8. PubMed ID: 9815646
[TBL] [Abstract][Full Text] [Related]
12. Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease.
Kraft A; Weindel K; Ochs A; Marth C; Zmija J; Schumacher P; Unger C; Marmé D; Gastl G
Cancer; 1999 Jan; 85(1):178-87. PubMed ID: 9921991
[TBL] [Abstract][Full Text] [Related]
13. Leukocytes and platelets of patients with cancer contain high levels of vascular endothelial growth factor.
Salven P; Orpana A; Joensuu H
Clin Cancer Res; 1999 Mar; 5(3):487-91. PubMed ID: 10100697
[TBL] [Abstract][Full Text] [Related]
14. Human carcinoma cells bind thrombospondin through a Mr 80,000/105,000 receptor.
Yabkowitz R; Dixit VM
Cancer Res; 1991 Jul; 51(14):3648-56. PubMed ID: 1712244
[TBL] [Abstract][Full Text] [Related]
15. Thrombospondins I and II messenger RNA expression in lung carcinoma: relationship with p53 alterations, angiogenic growth factors, and vascular density.
Fontanini G; Boldrini L; Calcinai A; Chinè S; Lucchi M; Mussi A; Angeletti CA; Basolo F; Bevilacqua G
Clin Cancer Res; 1999 Jan; 5(1):155-61. PubMed ID: 9918214
[TBL] [Abstract][Full Text] [Related]
16. Monoclonal antibody to human carcinoma-associated protein complex: quantitation in normal and tumor tissue.
Falcioni R; Sacchi A; Resau J; Kennel SJ
Cancer Res; 1988 Feb; 48(4):816-21. PubMed ID: 2448027
[TBL] [Abstract][Full Text] [Related]
17. Plasma thrombomodulin levels in lung cancer patients.
Yilmaz T; Akman M; Tutluoğlu B; Afrasyap L; Göylüsün V; Celik N
Panminerva Med; 1999 Jun; 41(2):125-8. PubMed ID: 10479910
[TBL] [Abstract][Full Text] [Related]
18. Serum osteoprotegerin levels in healthy controls and cancer patients.
Lipton A; Ali SM; Leitzel K; Chinchilli V; Witters L; Engle L; Holloway D; Bekker P; Dunstan CR
Clin Cancer Res; 2002 Jul; 8(7):2306-10. PubMed ID: 12114435
[TBL] [Abstract][Full Text] [Related]
19. Elevated plasma osteopontin in metastatic breast cancer associated with increased tumor burden and decreased survival.
Singhal H; Bautista DS; Tonkin KS; O'Malley FP; Tuck AB; Chambers AF; Harris JF
Clin Cancer Res; 1997 Apr; 3(4):605-11. PubMed ID: 9815727
[TBL] [Abstract][Full Text] [Related]
20. Osteopontin as a serologic marker for metastatic uveal melanoma: results of a pilot study.
Reiniger IW; Wolf A; Welge-Lüssen U; Mueller AJ; Kampik A; Schaller UC
Am J Ophthalmol; 2007 Apr; 143(4):705-7. PubMed ID: 17386288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
